However, no objective responses were observed with CCR2-CCL2 inhibitors when administrated as monotherapy in metastatic castration-resistant prostate cancer [160] or in combination chemotherapy in pancreatic cancer [161,162]. This evidence concerns the gene CCL2 and pancreatic neoplasm.